Skip to content

Opus Genetics IRD Depreciation

Depreciation at other companies

AbbVie logo
AbbVieABBV
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
AMP
Amphastar PharmaceuticalsAMPH

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's depreciation?
Opus Genetics (IRD) reported depreciation of $13K in Q1 2026.
How has Opus Genetics's depreciation changed year-over-year?
Opus Genetics's depreciation decreased by 0.0% year-over-year, from $13K to $13K.
What is the long-term trend for Opus Genetics's depreciation?
Over 4 years (2021 to 2025), Opus Genetics's depreciation has grown at a 90.8% compound annual growth rate (CAGR), from $4K to $53K.